Home - Fidoquel

The first and only FDA-approved phenobarbital tablet in the USA

Hope for dogs with idiopathic epilepsy

FIDOQUEL®-CA1 (phenobarbital tablets) are indicated for the control of seizures associated with idiopathic epilepsy in dogs.¹

A Purpose-Built Phenobarbital for Dogs

As the first and only phenobarbital option developed specifically for veterinary use, FIDOQUEL-CA1 offers an alternative to human phenobarbital products, which are not approved by the FDA for any use. FIDOQUEL-CA1 is manufactured to veterinary standards and provides dosing flexibility to support everyday clinical practice.

FIDOQUEL-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-578.

Predictable effectiveness

Studies on phenobarbital demonstrate that 82% of dogs achieved >50% seizure reduction, including 31% that became seizure-free.*¹

*Based on eight studies for a total of 311 dogs. 15% of dogs did not improve.

Professional Recognition

Phenobarbital use is supported by eight peer-reviewed publications, including the ACVIM and IVETF consensus guidelines.^**1

**ACVIM=American College of Veterinary Medicine; IVETF= International Veterinary Epilepsy Task Force

Formulated with purpose

Bisected tablets in multiple strengths for flexible, individualized dosing.¹

Available in 15–100 mg strengths

Twice-daily dosing with food

Beef-flavored tablets coming soon

FIDOQUEL-CA1 allows titration based on individual clinical response, giving you the flexibility to adjust therapy for seizure control and safety.

Practical Benefits for Your Practice

Eliminate Human Drug Workarounds

Stop explaining to clients why you're using human medications. FIDOQUEL-CA1 is purpose-built for dogs with veterinary-specific manufacturing standards.

Improve Client Conversations

When clients ask, "Is this the best option?", you can confidently say yes; it's FDA conditionally approved specifically for dogs like theirs.

Expert Support When You Need It

Direct access to Genus Lifesciences' technical team for dosing questions, adverse event guidance, and clinical support.

For use in
dogs only

Schedule IV Controlled Substance – Secure handling required

Have questions? Call our dedicated line for veterinary professionals:
1-833-599-7582

Lead the Way in Canine Seizure Control

FIDOQUEL-CA1 is available now for prescribing veterinarians.

To purchase FIDOQUEL-CA1, please contact your veterinary distributor.

Genus Lifesciences maintains active supply arrangements with all major veterinary distributors across the United States.

For a list of available distributors, please contact our sales team at Sales@GenusLifesciences.com

IMPORTANT SAFETY INFORMATION

Contraindicated in dogs with a history of hypersensitivity to phenobarbital.

Do not use in pregnant or lactating dogs due to risk of congenital malformations during fetal development and accumulation in the milk of lactating dogs. Safety in dogs that are intended for breeding, pregnant or lactating, or <6 months of age has not been established. Not for use in cats.

Monitor therapeutic, biochemical, hematology parameters, and adverse reactions, especially with concomitant medications and dose adjustments. Dogs with decreased liver function may be predisposed to phenobarbital toxicosis.

Not for use in humans. Due to risks of developmental effects, women who are pregnant or may become pregnant should handle and administer with caution. In case of accidental ingestion, skin reaction, or mucous membrane or eye exposure, contact a physician immediately and rinse exposed area thoroughly.

Keep out of reach of children and animals.

Drug Abuse, Addiction, and Diversion: Contains phenobarbital, a Schedule IV controlled substance with potential for abuse, misuse, addiction, and diversion. Store in a locked cabinet according to federal and state requirements.

See Prescribing Information for complete product details.

References:
1. FIDOQUEL-CA1 [prescribing information]. Allentown, PA: Genus Lifesciences Inc.; 2025.